Navigation Links
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/23/2012

EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time.  The conference will be held at the Boston Marriott Copley Place in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.Contact:  Mary Coleman Carney Noensie Savient Pharmaceuticals, Inc. Burns McClellan information@savient.com  cnoensie@burnsmc.com (732) 418-9300  (212) 213-0006SVNT - G


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
4. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
5. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
6. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
7. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
9. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
11. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured in The ... forefront of Gardant since it was founded in 1999. His drive and inquisitive nature ... than 40 new senior living communities. With his leadership, Gardant has grown to be ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... A ... over the last decade, student well-being has seriously declined. "When disenfranchised youth from ... education, join the Islamic State to turn the historic multi-ethnic and multi-religious powerhouses ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, and Omega Station”: ... Station” is the creation of published author, Chris Jackson. Chris Jackson grew up ... in the Dallas Independent School District teaching English. He is heavily involved in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... wear distributors and International relief organizations across the globe to provide effective protection ... lifestyle and work wear collections via insectshield.com . In the wake of ...
Breaking Medicine News(10 mins):